Previous 10 | Next 10 |
Aeglea BioTherapeutics (NASDAQ:AGLE) entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities in a registered direct offering for gross proceeds of ~$45M. The financing includes 10.75M shares at $1.6/sh...
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...
Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q1 GAAP EPS of -$0.37. Revenue of $1.36B. For further details see: Aeglea BioTherapeutics GAAP EPS of -$0.37, revenue of $1.36B
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates PR Newswire Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional ...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...
CarMax (NYSE:KMX) drew significant attention in Tuesday's pre-market action, falling on weaker-than-expected quarterly results. Starbucks (SBUX) also took its share of the spotlight, weighed down by an analyst's downgrade. Novartis (NVS) generated headlines as well, following reports that it ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com We’ve got a reverse stock split, clinical trial...
Aeglea BioTherapeutics (NASDAQ:AGLE) submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of pegzilarginase to treat Arginase 1 Deficiency (ARG1-D). The company has requested FDA priority review of the biologics license application (BLA). Aeglea (AGLE) adde...
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on nex...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...